ATE323084T1 - Für die behandlung von alzheimer krankheit geeignete makrocyclen - Google Patents

Für die behandlung von alzheimer krankheit geeignete makrocyclen

Info

Publication number
ATE323084T1
ATE323084T1 AT02752056T AT02752056T ATE323084T1 AT E323084 T1 ATE323084 T1 AT E323084T1 AT 02752056 T AT02752056 T AT 02752056T AT 02752056 T AT02752056 T AT 02752056T AT E323084 T1 ATE323084 T1 AT E323084T1
Authority
AT
Austria
Prior art keywords
disease
treatment
alzheimer
macrocycles
useful
Prior art date
Application number
AT02752056T
Other languages
English (en)
Inventor
Shon R Pulley
James P Beck
Ruth E Tenbrink
Original Assignee
Elan Pharm Inc
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, Pharmacia & Upjohn Co Llc filed Critical Elan Pharm Inc
Application granted granted Critical
Publication of ATE323084T1 publication Critical patent/ATE323084T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02752056T 2001-06-12 2002-06-12 Für die behandlung von alzheimer krankheit geeignete makrocyclen ATE323084T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29754601P 2001-06-12 2001-06-12
US33308301P 2001-11-19 2001-11-19

Publications (1)

Publication Number Publication Date
ATE323084T1 true ATE323084T1 (de) 2006-04-15

Family

ID=26970209

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02752056T ATE323084T1 (de) 2001-06-12 2002-06-12 Für die behandlung von alzheimer krankheit geeignete makrocyclen

Country Status (10)

Country Link
US (2) US6969709B2 (de)
EP (1) EP1404671B1 (de)
JP (1) JP2004534064A (de)
AT (1) ATE323084T1 (de)
BR (1) BR0210392A (de)
CA (1) CA2450202A1 (de)
DE (1) DE60210614T2 (de)
ES (1) ES2261699T3 (de)
MX (1) MXPA03011466A (de)
WO (1) WO2002100856A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360508A1 (en) 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
CA2512111A1 (en) 2003-01-07 2004-07-29 Merck And Co., Inc. Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
GB0325830D0 (en) * 2003-11-05 2003-12-10 Novartis Ag Organic compounds
ATE396990T1 (de) 2004-07-28 2008-06-15 Schering Corp Makrocyclische inhibitoren der beta-sekretase
BRPI0606636A2 (pt) * 2005-01-13 2009-07-07 Novartis Ag compostos macrocìclicos úteis como inibidores de bace
GB0500683D0 (en) * 2005-01-13 2005-02-23 Novartis Ag Organic compounds
JP2008535863A (ja) 2005-04-08 2008-09-04 コメンティス，インコーポレーテッド β−セクレターゼ活性を阻害する化合物およびその使用方法
WO2007021793A1 (en) * 2005-08-12 2007-02-22 Bristol-Myers Squibb Company Macrocyclic diaminopropanes as beta-secretase inhibitors
GB0526614D0 (en) * 2005-12-30 2006-02-08 Novartis Ag Organic compounds
BRPI0715440A2 (pt) * 2006-07-20 2013-07-23 Novartis Ag compostos macrocÍclicos éteis como inibidores de bace
CA2656869A1 (en) * 2006-07-20 2008-01-24 Novartis Ag Macrocyclic lactams
US7678784B2 (en) 2006-11-20 2010-03-16 Bristol-Myers Squibb Company Oxime-containing macrocyclic acyl guanidines as β-secretase inhibitors
US7772221B2 (en) 2007-02-09 2010-08-10 Bristol-Meyers Squibb Company Diaminopropane derived macrocycles as inhibitors of β amyloid production
US20100063013A1 (en) * 2007-03-26 2010-03-11 Renata Oballa Cathepsin cysteine protease inhibitors
US7732434B2 (en) 2007-04-20 2010-06-08 Bristol-Myers Squibb Company Macrocyclic acyl guanidines as beta-secretase inhibitors
WO2014144346A1 (en) * 2013-03-15 2014-09-18 The Board Of Regents Of The University Of Texas System Use of inhibitors of mtor to improve vascular functions in apoe4 carriers
DK3089737T3 (da) 2013-12-31 2021-12-13 Rapamycin Holdings Llc Orale rapamycin-nanopartikelpræparater og anvendelse.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM982594A0 (en) 1994-12-02 1995-01-05 University Of Queensland, The HIV protease inhibitors
WO2000077030A1 (en) * 1999-06-15 2000-12-21 Elan Pharmaceuticals, Inc. Statine-derived tetrapeptide inhibitors of beta-secretase

Also Published As

Publication number Publication date
MXPA03011466A (es) 2004-07-01
US20030236199A1 (en) 2003-12-25
CA2450202A1 (en) 2002-12-19
DE60210614T2 (de) 2007-03-01
US7442691B2 (en) 2008-10-28
EP1404671A1 (de) 2004-04-07
BR0210392A (pt) 2004-10-13
EP1404671B1 (de) 2006-04-12
WO2002100856A1 (en) 2002-12-19
ES2261699T3 (es) 2006-11-16
DE60210614D1 (de) 2006-05-24
US6969709B2 (en) 2005-11-29
US20060040910A1 (en) 2006-02-23
JP2004534064A (ja) 2004-11-11

Similar Documents

Publication Publication Date Title
TW200512195A (en) Benzamide 2-hydroxy-3-diaminoalkanes
MXPA04000328A (es) Derivados de alfa-hidroxiamida estatina para tratamiento de enfermedad de alzheimer.
ATE323084T1 (de) Für die behandlung von alzheimer krankheit geeignete makrocyclen
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
TW200505418A (en) Phenacyl 2-hydroxy-3-diaminoalkanes
MXPA04006575A (es) Amino carboxamidas sustituidas para el tratamiento de la enfermedad de alzheimer.
MXPA04000338A (es) Diamindioles para tratamiento de enfermedad de alzheimer.
MXPA04003245A (es) Hidroxipropilaminas.
AP2004002952A0 (en) N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds.
TW200505828A (en) Substituted ureas and carbamates useful in the treatment of alzheimer's disease
WO2004022523A3 (en) 1, 3-diamino-2-hydroxypropane prodrug derivatives
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
MXPA05002420A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos.
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
EP1689713A4 (de) Benzylether und benzylaminoverbindungen als inhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE326964T1 (de) Aminosäurederivate zur behandlung der alzheimer- krankheit
MXPA03011502A (es) Aminoalcoholes sustituidos utiles en tratamiento de enfermedad de alzheimer.
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
WO2004029019A3 (en) Compounds for the treatment of alzheimer’s disease
DE60219680D1 (de) Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
ATE323489T1 (de) Verwendung von bicyklischen verbindungen für die behandlung von alzheimer
WO2005042472A3 (en) Hydroxypropyl amides for the treatment of alzheimer’s disease
ECSP044940A (es) N-(3-amino-2-hidroxil-propil) compuestos substitutos de alquilamida
EA200500382A1 (ru) Соединения тиазола для лечения нейродегенеративных расстройств

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties